Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion type Assertion NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_head.
- NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion description "[The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_provenance.
- NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion evidence source_evidence_literature NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_provenance.
- NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion SIO_000772 19850635 NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_provenance.
- NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion wasDerivedFrom gad-20130706 NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_provenance.
- NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_assertion wasGeneratedBy ECO_0000203 NP62072.RAbhEalJ6vyIq-KFo2SQVWZdUpdLI0cpgZU6BIzRYPp8c130_provenance.